Filing summary: CryoLife, Inc. FY 2019
Issuer identification: The supplied filing is CryoLife, Inc.’s Form 10-K, filed February 19, 2020, for the fiscal year ended December 31, 2019. It identifies the company as CryoLife (NYSE: CRY), not Artivion; verify the issuer and security before relying on this summary.
Business context and reporting period
CryoLife makes and distributes medical devices and preserves human cardiac and vascular tissues used mainly in cardiac and vascular surgery. Its reporting segments are Medical Devices and Preservation Services. The filing includes full-year results and unaudited fourth-quarter results.
Financial performance
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | $276.2 million | $262.8 million |
| Gross margin | $183.0 million; 66% | $173.0 million; 66% |
| Operating income | $17.0 million | $9.3 million |
| Net income (loss) | $1.7 million | $(2.8) million |
| Diluted earnings (loss) per share | $0.05 | $(0.08) |
| Operating cash flow | $15.8 million | $9.9 million |
| Capital expenditures | $8.1 million | $5.8 million |
Revenue grew 5% year over year (7% excluding foreign-exchange effects). Medical Device revenue rose 5% to $197.2 million; Preservation Services revenue rose 5% to $79.0 million. Key annual product changes included On-X up 12%, BioGlue up 3%, JOTEC up 3%, cardiac tissue preservation up 15%, and vascular tissue preservation down 4%.
In Q4 2019, revenue was $69.7 million, up 3% from $67.8 million. Gross margin was 67% in both periods. The company reported a quarterly net loss of $0.7 million, versus a $0.8 million loss in Q4 2018.
At year-end, cash and cash equivalents were $33.8 million, working capital was $142.2 million, and the current ratio was 4:1. The balance sheet reported $215.7 million of debt net of unamortized issuance costs; scheduled principal obligations totaled $223.2 million. The $30 million revolving facility was undrawn and fully available. Long-term debt is largely variable-rate and matures in 2024.
Material changes versus prior period
- Revenue and operating income increased; the company returned to modest annual net income from a 2018 net loss. Gross margin percentage was unchanged.
- Operating cash flow improved, while cash and cash equivalents declined to $33.8 million from $41.5 million. Investing outflows increased to $23.9 million, including $15.0 million paid under Endospan agreements and $8.1 million of capital expenditures.
- On-X growth and higher cardiac tissue shipments were important revenue drivers; vascular preservation revenue fell. JOTEC remained about 24% of annual revenue.
- Adoption of lease accounting added operating lease assets and liabilities; year-end operating lease liabilities were $23.4 million.
Outlook, risks, contingencies, and unusual items
- The filing provides no specific consolidated revenue or earnings guidance. Management stated that cash from operations and existing cash were expected to cover current operating liquidity needs for at least 12 months, while noting potential financing needs if significant business development occurs.
- Management expected to submit PerClot’s U.S. PMA application in the second half of 2020; limited NEXUS distribution had begun in Europe. CryoLife also planned to start the PROACT Xa trial in 2020. These are expectations, not assured outcomes.
- Endospan arrangements included a $9 million NEXUS distribution fee, a $1 million option fee, and a $5 million secured loan funded in 2019. CryoLife could advance two further $5 million loan tranches subject to milestones. A separate option to acquire Endospan was priced at $350–$450 million upon specified FDA-approval timing; it was not a completed acquisition.
- Material operating and regulatory risks include reliance on single-source suppliers, the interruption in CardioGenesis handpiece supply (management anticipated resumption in the second half of 2020), possible FDA reclassification of CryoValve SGPV, and transfer of BioGlue and PhotoFix European certifications to a new Notified Body.
- The filing identifies the coronavirus outbreak as a potential risk to China-related sales, supply chain activity, and BioGlue regulatory approval. It also cites foreign-exchange exposure, competitive pressure, acquisition integration and debt burdens, and variable tissue supply and yields.
- A Q4 business-email compromise redirected a $2.6 million vendor payment. The company expected cyber insurance to cover all but a de minimis amount of unrecovered losses; it reported a significant control deficiency, said payment controls were enhanced, and considered the deficiency remediated.
- Management reported no pending legal matter believed likely to have a material adverse effect, while noting that outcomes in ordinary-course proceedings remain uncertain. Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Confirm that CryoLife/CRY is the intended issuer; the request metadata names Artivion, while this filing names CryoLife.
- Review the full debt agreement, variable-rate exposure, covenants, and the substantial 2024 principal maturity.
- Check subsequent progress on PerClot FDA submission, PROACT Xa enrollment, NEXUS commercialization, and any Endospan loan milestones or acquisition-option decisions.
- Verify resolution of the BioGlue and PhotoFix European certification transfer and the FDA’s proposed allograft-heart-valve reclassification.
- Assess whether CardioGenesis handpiece supply resumed as anticipated and whether the cyber-insurance recovery and remediation were completed as described.
- Examine tissue yields, deferred preservation cost assumptions, and product-level trends, particularly vascular preservation, which declined in 2019.